SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Bill Wexler's Dog Pound
REFR 1.560-2.5%Nov 7 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike M who wrote (2119)7/14/1999 9:52:00 AM
From: Hank  Read Replies (1) of 10293
 
I might point out that the only way pleconaril will ever be able to effectively compete with OTC medicines like zicam is if IT becomes approved for OTC sales. That is something that is many many years away. Initially, IF pleconaril is approved by the FDA, it will be a prescription drug that will be used for patients who suffer severe viral symptoms such as meningitis. Even if VPHM tried to get Dr's to prescribe it for people with an average cold, how many people would bother (especially if they didn't have prescription coverage)? Furthermore, for those who did have prescription coverage, how many medical insurance plans are going absorb a potentially huge cost for a drug that treats a common illness that is generally not life threatening?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext